A citation-based method for searching scientific literature

Debyani Chakravarty, Amber Johnson, Jeffrey Sklar, Neal I Lindeman, Kathleen Moore, Shridar Ganesan, Christine M Lovly, Jane Perlmutter, Stacy W Gray, Jimmy Hwang, Christopher Lieu, Fabrice André, Nilofer Azad, Mitesh Borad, Laura Tafe, Hans Messersmith, Mark Robson, Funda Meric-Bernstam. J Clin Oncol 2022
Times Cited: 3







List of co-cited articles
3 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation.
Mark Robson, Seock-Ah Im, Elżbieta Senkus, Binghe Xu, Susan M Domchek, Norikazu Masuda, Suzette Delaloge, Wei Li, Nadine Tung, Anne Armstrong,[...]. N Engl J Med 2017
66

Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation.
Jennifer K Litton, Hope S Rugo, Johannes Ettl, Sara A Hurvitz, Anthony Gonçalves, Kyung-Hun Lee, Louis Fehrenbacher, Rinat Yerushalmi, Lida A Mina, Miguel Martin,[...]. N Engl J Med 2018
802
66

Homologous Recombination Deficiency: Concepts, Definitions, and Assays.
Mark D Stewart, Diana Merino Vega, Rebecca C Arend, Jonathan F Baden, Olena Barbash, Nike Beaubier, Grace Collins, Tim French, Negar Ghahramani, Patsy Hinson,[...]. Oncologist 2022
2
100

Prevalence of Germline Findings Among Tumors From Cancer Types Lacking Hereditary Testing Guidelines.
Timothy A Yap, Arya Ashok, Jessica Stoll, Elizabeth Mauer, Vanessa M Nepomuceno, Kimberly L Blackwell, Judy E Garber, Funda Meric-Bernstam. JAMA Netw Open 2022
1
100

Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade.
Dung T Le, Jennifer N Durham, Kellie N Smith, Hao Wang, Bjarne R Bartlett, Laveet K Aulakh, Steve Lu, Holly Kemberling, Cara Wilt, Brandon S Luber,[...]. Science 2017
33

Yield and Utility of Germline Testing Following Tumor Sequencing in Patients With Cancer.
Stephen E Lincoln, Robert L Nussbaum, Allison W Kurian, Sarah M Nielsen, Kingshuk Das, Scott Michalski, Shan Yang, Nhu Ngo, Amie Blanco, Edward D Esplin. JAMA Netw Open 2020
27
33

Blood RNA analysis can increase clinical diagnostic rate and resolve variants of uncertain significance.
Htoo A Wai, Jenny Lord, Matthew Lyon, Adam Gunning, Hugh Kelly, Penelope Cibin, Eleanor G Seaby, Kerry Spiers-Fitzgerald, Jed Lye, Sian Ellard,[...]. Genet Med 2020
46
33

Mutation Detection in Patients With Advanced Cancer by Universal Sequencing of Cancer-Related Genes in Tumor and Normal DNA vs Guideline-Based Germline Testing.
Diana Mandelker, Liying Zhang, Yelena Kemel, Zsofia K Stadler, Vijai Joseph, Ahmet Zehir, Nisha Pradhan, Angela Arnold, Michael F Walsh, Yirong Li,[...]. JAMA 2017
232
33

Comprehensive Analysis of Hypermutation in Human Cancer.
Brittany B Campbell, Nicholas Light, David Fabrizio, Matthew Zatzman, Fabio Fuligni, Richard de Borja, Scott Davidson, Melissa Edwards, Julia A Elvin, Karl P Hodel,[...]. Cell 2017
412
33

Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology.
Sue Richards, Nazneen Aziz, Sherri Bale, David Bick, Soma Das, Julie Gastier-Foster, Wayne W Grody, Madhuri Hegde, Elaine Lyon, Elaine Spector,[...]. Genet Med 2015
33

Germ-line BRCA1 mutation is an adverse prognostic factor in Ashkenazi Jewish women with breast cancer.
W D Foulkes, N Wong, J S Brunet, L R Bégin, J C Zhang, J J Martinez, F Rozen, P N Tonin, S A Narod, S E Karp,[...]. Clin Cancer Res 1997
96
33

BRCA2 acts as a RAD51 loader to facilitate telomere replication and capping.
Sophie Badie, Jose M Escandell, Peter Bouwman, Ana Rita Carlos, Maria Thanasoula, Maria M Gallardo, Anitha Suram, Isabel Jaco, Javier Benitez, Utz Herbig,[...]. Nat Struct Mol Biol 2010
122
33

Breast cancer prognosis in BRCA1 and BRCA2 mutation carriers: an International Prospective Breast Cancer Family Registry population-based cohort study.
Pamela J Goodwin, Kelly-Anne Phillips, Dee W West, Marguerite Ennis, John L Hopper, Esther M John, Frances P O'Malley, Roger L Milne, Irene L Andrulis, Michael L Friedlander,[...]. J Clin Oncol 2012
99
33

Why BRCA mutations are not tumour-agnostic biomarkers for PARP inhibitor therapy.
Nicola J Curtin, Yvette Drew, Sweta Sharma-Saha. Nat Rev Clin Oncol 2019
13
33

Survival and recurrence after breast cancer in BRCA1/2 mutation carriers.
Mahmoud El-Tamer, Donna Russo, Andrea Troxel, Lourdes P Bernardino, Robert Mazziotta, Alison Estabrook, Beth-Ann Ditkoff, Freya Schnabel, Mahesh Mansukhani. Ann Surg Oncol 2004
44
33

Survival analysis of carboplatin added to an anthracycline/taxane-based neoadjuvant chemotherapy and HRD score as predictor of response-final results from GeparSixto.
S Loibl, K E Weber, K M Timms, E P Elkin, E Hahnen, P A Fasching, B Lederer, C Denkert, A Schneeweiss, S Braun,[...]. Ann Oncol 2018
122
33

TBCRC 031: Randomized Phase II Study of Neoadjuvant Cisplatin Versus Doxorubicin-Cyclophosphamide in Germline BRCA Carriers With HER2-Negative Breast Cancer (the INFORM trial).
Nadine Tung, Banu Arun, Michele R Hacker, Erin Hofstatter, Deborah L Toppmeyer, Steven J Isakoff, Virginia Borges, Robert D Legare, Claudine Isaacs, Antonio C Wolff,[...]. J Clin Oncol 2020
50
33

Phase II clinical trial of gemcitabine plus oxaliplatin in patients with metastatic pancreatic adenocarcinoma with a family history of pancreatic/breast/ovarian/prostate cancer or personal history of breast/ovarian/prostate cancer (FABRIC study).
Naohiro Okano, Chigusa Morizane, Shogo Nomura, Hideaki Takahashi, Hidetaka Tsumura, Hironaga Satake, Nobumasa Mizuno, Kunihiro Tsuji, Kazuhiko Shioji, Akinori Asagi,[...]. Int J Clin Oncol 2020
5
33

Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer.
Andrew N J Tutt, Judy E Garber, Bella Kaufman, Giuseppe Viale, Debora Fumagalli, Priya Rastogi, Richard D Gelber, Evandro de Azambuja, Anitra Fielding, Judith Balmaña,[...]. N Engl J Med 2021
176
33

Phase III study of iniparib plus gemcitabine and carboplatin versus gemcitabine and carboplatin in patients with metastatic triple-negative breast cancer.
Joyce O'Shaughnessy, Lee Schwartzberg, Michael A Danso, Kathy D Miller, Hope S Rugo, Marcus Neubauer, Nicholas Robert, Beth Hellerstedt, Mansoor Saleh, Paul Richards,[...]. J Clin Oncol 2014
184
33

Non-small cell lung cancer cells with deficiencies in homologous recombination genes are sensitive to PARP inhibitors.
Wenchao Ji, Xiang Weng, Danhua Xu, Shufan Cai, Honggang Lou, Ling Ding. Biochem Biophys Res Commun 2020
8
33

Frequent Homologous Recombination Deficiency in High-grade Endometrial Carcinomas.
Marthe M de Jonge, Aurélie Auguste, Lise M van Wijk, Philip C Schouten, Matty Meijers, Natalja T Ter Haar, Vincent T H B M Smit, Remi A Nout, Mark A Glaire, David N Church,[...]. Clin Cancer Res 2019
68
33

Veliparib with carboplatin and paclitaxel in BRCA-mutated advanced breast cancer (BROCADE3): a randomised, double-blind, placebo-controlled, phase 3 trial.
Véronique Diéras, Hyo S Han, Bella Kaufman, Hans Wildiers, Michael Friedlander, Jean-Pierre Ayoub, Shannon L Puhalla, Igor Bondarenko, Mario Campone, Erik H Jakobsen,[...]. Lancet Oncol 2020
91
33

BRCA Genes: The Role in Genome Stability, Cancer Stemness and Therapy Resistance.
Ielizaveta Gorodetska, Iryna Kozeretska, Anna Dubrovska. J Cancer 2019
68
33

Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial.
Sibylle Loibl, Joyce O'Shaughnessy, Michael Untch, William M Sikov, Hope S Rugo, Mark D McKee, Jens Huober, Mehra Golshan, Gunter von Minckwitz, David Maag,[...]. Lancet Oncol 2018
323
33

Modification of Homologous Recombination Deficiency Score Threshold and Association with Long-Term Survival in Epithelial Ovarian Cancer.
Jeffrey A How, Amir A Jazaeri, Bryan Fellman, Molly S Daniels, Suzanna Penn, Cara Solimeno, Ying Yuan, Kathleen Schmeler, Jerry S Lanchbury, Kirsten Timms,[...]. Cancers (Basel) 2021
9
33

Homologous recombination in DNA repair and DNA damage tolerance.
Xuan Li, Wolf-Dietrich Heyer. Cell Res 2008
520
33

Rucaparib in Men With Metastatic Castration-Resistant Prostate Cancer Harboring a BRCA1 or BRCA2 Gene Alteration.
Wassim Abida, Akash Patnaik, David Campbell, Jeremy Shapiro, Alan H Bryce, Ray McDermott, Brieuc Sautois, Nicholas J Vogelzang, Richard M Bambury, Eric Voog,[...]. J Clin Oncol 2020
190
33

Family history as a marker of platinum sensitivity in pancreatic adenocarcinoma.
David Fogelman, Elizabeth A Sugar, George Oliver, Neeraj Shah, Alison Klein, Christine Alewine, Huamin Wang, Milind Javle, Rachna Shroff, Robert A Wolff,[...]. Cancer Chemother Pharmacol 2015
43
33

Prospective Evaluation of Germline Alterations in Patients With Exocrine Pancreatic Neoplasms.
Maeve A Lowery, Winston Wong, Emmet J Jordan, Jonathan W Lee, Yelena Kemel, Joseph Vijai, Diana Mandelker, Ahmet Zehir, Marinela Capanu, Erin Salo-Mullen,[...]. J Natl Cancer Inst 2018
108
33

Platinum-Based Chemotherapy in Metastatic Prostate Cancer With DNA Repair Gene Alterations.
Jose Mauricio Mota, Ethan Barnett, Jones T Nauseef, Bastien Nguyen, Konrad H Stopsack, Andreas Wibmer, Jessica R Flynn, Glenn Heller, Daniel C Danila, Dana Rathkopf,[...]. JCO Precis Oncol 2020
46
33

Stereospecific PARP trapping by BMN 673 and comparison with olaparib and rucaparib.
Junko Murai, Shar-Yin N Huang, Amèlie Renaud, Yiping Zhang, Jiuping Ji, Shunichi Takeda, Joel Morris, Beverly Teicher, James H Doroshow, Yves Pommier. Mol Cancer Ther 2014
422
33

Homologous recombination deficiency (HRD) score in germline BRCA2- versus ATM-altered prostate cancer.
Tamara L Lotan, Harsimar B Kaur, Daniela C Salles, Sanjana Murali, Edward M Schaeffer, Jerry S Lanchbury, William B Isaacs, Robert Brown, Andrea L Richardson, Olivier Cussenot,[...]. Mod Pathol 2021
21
33

Homologous Recombination Deficiency (HRD) Score Predicts Response to Platinum-Containing Neoadjuvant Chemotherapy in Patients with Triple-Negative Breast Cancer.
Melinda L Telli, Kirsten M Timms, Julia Reid, Bryan Hennessy, Gordon B Mills, Kristin C Jensen, Zoltan Szallasi, William T Barry, Eric P Winer, Nadine M Tung,[...]. Clin Cancer Res 2016
438
33

Germline Mutation Status, Pathological Complete Response, and Disease-Free Survival in Triple-Negative Breast Cancer: Secondary Analysis of the GeparSixto Randomized Clinical Trial.
Eric Hahnen, Bianca Lederer, Jan Hauke, Sibylle Loibl, Sandra Kröber, Andreas Schneeweiss, Carsten Denkert, Peter A Fasching, Jens U Blohmer, Christian Jackisch,[...]. JAMA Oncol 2017
193
33

Clinicopathological features of homologous recombination-deficient epithelial ovarian cancers: sensitivity to PARP inhibitors, platinum, and survival.
Asima Mukhopadhyay, Elizabeth R Plummer, Ahmed Elattar, San Soohoo, Bisha Uzir, Jennifer E Quinn, W Glenn McCluggage, Perry Maxwell, Harriet Aneke, Nicola J Curtin,[...]. Cancer Res 2012
76
33

Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer.
Mansoor R Mirza, Bradley J Monk, Jørn Herrstedt, Amit M Oza, Sven Mahner, Andrés Redondo, Michel Fabbro, Jonathan A Ledermann, Domenica Lorusso, Ignace Vergote,[...]. N Engl J Med 2016
33

Pan-Cancer Analysis of BRCA1 and BRCA2 Genomic Alterations and Their Association With Genomic Instability as Measured by Genome-Wide Loss of Heterozygosity.
Ethan S Sokol, Dean Pavlick, Hossein Khiabanian, Garrett M Frampton, Jeffrey S Ross, Jeffrey P Gregg, Primo N Lara, Steffi Oesterreich, Neeraj Agarwal, Andrea Necchi,[...]. JCO Precis Oncol 2020
51
33

Talazoparib monotherapy in metastatic castration-resistant prostate cancer with DNA repair alterations (TALAPRO-1): an open-label, phase 2 trial.
Johann S de Bono, Niven Mehra, Giorgio V Scagliotti, Elena Castro, Tanya Dorff, Adam Stirling, Arnulf Stenzl, Mark T Fleming, Celestia S Higano, Fred Saad,[...]. Lancet Oncol 2021
32
33

Homologous Recombination Deficiency: Exploiting the Fundamental Vulnerability of Ovarian Cancer.
Panagiotis A Konstantinopoulos, Raphael Ceccaldi, Geoffrey I Shapiro, Alan D D'Andrea. Cancer Discov 2015
414
33

Response to neoadjuvant systemic therapy for breast cancer in BRCA mutation carriers and noncarriers: a single-institution experience.
Banu Arun, Soley Bayraktar, Diane D Liu, Angelica M Gutierrez Barrera, Deann Atchley, Lajos Pusztai, Jennifer Keating Litton, Vicente Valero, Funda Meric-Bernstam, Gabriel N Hortobagyi,[...]. J Clin Oncol 2011
114
33

Platinum response characteristics of patients with pancreatic ductal adenocarcinoma and a germline BRCA1, BRCA2 or PALB2 mutation.
Max M Wattenberg, Daniella Asch, Shun Yu, Peter J O'Dwyer, Susan M Domchek, Katherine L Nathanson, Mark A Rosen, Gregory L Beatty, Evan S Siegelman, Kim A Reiss. Br J Cancer 2020
74
33

Retrospective Survival Analysis of Patients With Advanced Pancreatic Ductal Adenocarcinoma and Germline BRCA or PALB2 Mutations.
Kim A Reiss, Shun Yu, Renae Judy, Heather Symecko, Katherine L Nathanson, Susan M Domchek. JCO Precis Oncol 2018
9
33

Outcomes in Patients With Pancreatic Adenocarcinoma With Genetic Mutations in DNA Damage Response Pathways: Results From the Know Your Tumor Program.
Michael J Pishvaian, Edik M Blais, Jonathan R Brody, Lola Rahib, Emily Lyons, Patricia De Arbeloa, Andrew Hendifar, Sameh Mikhail, Vincent Chung, Davendra P S Sohal,[...]. JCO Precis Oncol 2019
7
33

FDA Approval Summary: Olaparib Monotherapy or in Combination with Bevacizumab for the Maintenance Treatment of Patients with Advanced Ovarian Cancer.
Shaily Arora, Sanjeeve Balasubramaniam, Hui Zhang, Tara Berman, Preeti Narayan, Daniel Suzman, Erik Bloomquist, Shenghui Tang, Yutao Gong, Rajeshwari Sridhara,[...]. Oncologist 2021
33
33

Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer.
Kathleen Moore, Nicoletta Colombo, Giovanni Scambia, Byoung-Gie Kim, Ana Oaknin, Michael Friedlander, Alla Lisyanskaya, Anne Floquet, Alexandra Leary, Gabe S Sonke,[...]. N Engl J Med 2018
33

DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer.
Joaquin Mateo, Suzanne Carreira, Shahneen Sandhu, Susana Miranda, Helen Mossop, Raquel Perez-Lopez, Daniel Nava Rodrigues, Dan Robinson, Aurelius Omlin, Nina Tunariu,[...]. N Engl J Med 2015
33

Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer.
Robert L Coleman, Gini F Fleming, Mark F Brady, Elizabeth M Swisher, Karina D Steffensen, Michael Friedlander, Aikou Okamoto, Kathleen N Moore, Noa Efrat Ben-Baruch, Theresa L Werner,[...]. N Engl J Med 2019
343
33

Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working Group.
F Mosele, J Remon, J Mateo, C B Westphalen, F Barlesi, M P Lolkema, N Normanno, A Scarpa, M Robson, F Meric-Bernstam,[...]. Ann Oncol 2020
221
33



Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.